The Inflation Reduction Act (IRA) has meant a number of changes for the US pharmaceutical industry. In our latest blog from Symphony Health, an ICON plc company, we discuss two provisions and how they interact to induce cost-related change: https://ow.ly/5nwy50V1Tzm #dataintegrity #healthcaredata #dataprovenance #datareliability #datacontinuity
Info
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
Externer Link zu ICON plc
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Dublin
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs und Global Patient Insights & Engagement
Orte
Beschäftigte von ICON plc
Updates
-
Antibody-Drug Conjugates (ADCs) are revolutionising the pharmaceutical landscape, offering groundbreaking therapeutic potential. However, their analysis presents unique challenges requiring specialised bioanalytical approaches. During this webinar hosted by Bioanalysis Zone, ICON will discuss the optimisation of ADC assays, including selecting the right bioanalytical assays, and key development & validation parameters for ADCs. Register here: https://ow.ly/TXQ750V1Nfa #ADCBioanalysis #BioanalyticalAssays
-
-
Looking to optimise clinical trial execution while building internal capabilities? See how a midsized biotech transitioned from managing five CROs to using a blended delivery model custom designed and executed by ICON. Read about the cost savings, operational efficiency and long-term scalability built into the strategy: https://ow.ly/a6p750UZaIT
-
-
Diversity in clinical trials is essential for developing generalisable treatments, but in a recent survey, only 26% of CNS drug developers reported using diversity plans. Learn best practices for conducting inclusive neurodegenerative trials in our whitepaper. Download the whitepaper: https://ow.ly/tTbX50UU6ip
-
-
ADCs form a group of new, pharmaceutically active molecules promising great benefit to patients. The analysis of ADCs has several unique challenges and requires both ligand binding assays as well as LC-MS/MS assays. During this webinar, ICON will discuss the complexities of ADC assays and how they can be best optimised. Register here: https://ow.ly/FVru50V1Nqs #ADCBioanalysis #BioanalyticalAssays
-
-
In only a few days, Riejanne Bax-Seigers will discuss the latest industry practices for in-study cut point setting trends for clinical immunogenicity assays at #EIP 2025. Come along to her session on February 25 at 15:45pm to hear more. https://ow.ly/7zmF50UMAgz
-
-
ICON’s Patient Centred Outcomes (PCO) team supports National Caregivers Day. With over 45 staff located across Europe and North America, the PCO team are constantly working to advance knowledge and research across numerous therapeutic areas, including understanding the burden on caregivers. The PCO team have produced a wide range of research involving family and informal caregivers. Here are some of PCO’s key publications which shine a spotlight on the valuable insights caregivers bring to our research. • Development of a signs and symptoms outcome measure for caregivers of patients with methylmalonic acidemia and propionic acidemia (MMAPAQ) https://ow.ly/ZiXt50UYrln • Patient and Caregiver Perspectives on Care-Seeking During a Vaso-Occlusive Crisis in Sickle Cell Disease: Results from Qualitative Interviews in Canada https://ow.ly/gS2G50UYrll • Lived experiences of patients with distal renal tubular acidosis treated with ADV7103 and of their caregivers: a qualitative study. https://ow.ly/FAiq50UYrlx • Perceived Unmet Needs in Patients Living With Advanced Bladder Cancer and Their Caregivers: Infodemiology Study Using Data From Social Media in the United States. https://ow.ly/QSS550UYrlH • Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder. https://ow.ly/4jP950UYrlk #NationalCaregiversDay #ICONplc #Caregivers #PatientCentredOutcomes
-
-
Rare Disease Day takes place on February 28. In rare disease research, where patient populations are small and heterogenous, N-of-1 trials offer an opportunity to determine optimal intervention for an individual patient using objective, data-driven criteria. Explore their use and potential in our on-demand webinar: https://ow.ly/cEJg50V3wbW #RareDiseaseDay #ShareYourColours
-
-
Plain language summaries make complex information accessible to everyone. They bridge the gap between experts and the public, ensuring clarity and understanding in clinical research. https://ow.ly/Xncx50UYliH #PlainLanguage #Communication #Accessibility
-
-
ADCs are transforming cancer treatment by combining targeted monoclonal antibodies with powerful cytotoxic agents. However their complexity poses bioanalytical challenges. Scientists face major challenges due to ADC heterogeneity, variable drug-to-antibody ratios, and the need for precise pharmacokinetic (PK) and immunogenicity assessments. Advanced techniques like LC–MS/MS and ligand-binding assays are essential to tackle these obstacles. In this Bioanalysis Zone spotlight ICON experts share insights, challenges and solutions in ADC bioanalytics. Read on to learn more: https://ow.ly/UT0p50UYrXw #ADC #bioanalysis #oncology
-
Verbundene Seiten
Ähnliche Seiten
Finanzierung
ICON plc
Insgesamt 1 Finanzierungsrunde
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
2.000.000.000,00 $